These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Preparing for the future. Cox S Posit Aware; 1997; 8(2):10-1. PubMed ID: 11364448 [TBL] [Abstract][Full Text] [Related]
47. Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy. Parienti JJ AIDS; 2002 Oct; 16(15):2097; author reply 2098. PubMed ID: 12370515 [No Abstract] [Full Text] [Related]
48. A new HAART on the horizon says the proof is in the potency. AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218 [TBL] [Abstract][Full Text] [Related]
49. After the drugs: what's next? Schouten JT Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085 [TBL] [Abstract][Full Text] [Related]
50. Preliminary report on 1592. AIDS Clin Care; 1997 Sep; 9(9):71. PubMed ID: 11364756 [TBL] [Abstract][Full Text] [Related]
51. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061 [TBL] [Abstract][Full Text] [Related]
52. CRIA clinical trials. Newsline People AIDS Coalit N Y; 1998 Sep; ():59. PubMed ID: 11367496 [TBL] [Abstract][Full Text] [Related]
53. DMP 266 study opens at Jefferson. Crit Path AIDS Proj; 1997; (No 32):30-1. PubMed ID: 11364440 [TBL] [Abstract][Full Text] [Related]
56. Protease inhibitor combos. Newsline People AIDS Coalit N Y; 1998 Feb; ():36-7. PubMed ID: 11367448 [TBL] [Abstract][Full Text] [Related]
57. New drug pricing consensus letter, sign-ons requested. AIDS Treat News; 1998 Sep; (302):4. PubMed ID: 11365762 [TBL] [Abstract][Full Text] [Related]
58. Sustiva added to three-drug combination. AIDS Patient Care STDS; 1998 Oct; 12(10):803. PubMed ID: 11362030 [No Abstract] [Full Text] [Related]
59. [FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment]. Allerg Immunol (Paris); 1998 Oct; 30(8):268-70. PubMed ID: 9846197 [No Abstract] [Full Text] [Related]
60. [The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage]. Duval X Presse Med; 2000 Feb; 29(5):253-6. PubMed ID: 10701407 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]